AmyriAD Therapeutics B.V.

Privately held: no public share price · Netherlands

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Undisclosed / early pipeline
Schizophrenia
Cognitive Impairment Associated with Schizophrenia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 July 2025Topline resultInidascamine (RL-007)Phase 2b CIAS topline: inidascamine missed the primary endpoint
Recognify Life Sciences · Source ↗

Financial reports

No financial reports recorded.